Additionally, although it is early days, measuring the levels of circANRIL/linear ANRIL, might offer a prognostic value and help improve CAD risk stratification or allow to better monitor treatment response or disease recurrence.Yet, since circANRIL levels are reduced in plaque tissue, and since circANRIL has been found to be anti-atherogenic with or without co-existing linear ANRIL, increasing circANRIL abundance in patients could also be of therapeutic relevance. This evidence concerns the gene CDKN2B-AS1 and coronary artery disorder.